Hypersensitivity reactions to antiretroviral agents in HIV-infected patients;Reacciones de hipersensibilidad a antirretrovirales en pacientes con infección por el virus de la inmunodeficiencia humana

Medicina Clinica

Volumn 128, Issue 2, 2007, Pages 61-69

  Marcos Bravo, M Carmen ^a   Ocampo Hermida, Antonio ^a   Moreno Rodilla, Ester ^b  

^a Complexo Hospitalario Universitario Xeral Cíes ^*  (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Adverse drug reactions; Allergy; Antiretroviral agents; HIV; Hypersensitivity

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DELAVIRDINE; EFAVIRENZ; ENFUVIRTIDE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL PAIN; ASTHENIA; BONE MARROW TOXICITY; DIARRHEA; DRUG INDUCED DISEASE; FATTY LIVER; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; INFECTION; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER TOXICITY; MALAISE; MENTAL DISEASE; METABOLIC DISORDER; MYOPATHY; NAUSEA; NEUROLOGIC DISEASE; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; RASH; RESEARCH; REVIEW; SKIN DISEASE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; URTICARIA; VOMITING;

EID: 33846903834     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(07)72487-9     Document Type: Review

References (100)

1. Pirmohamed M, Kevin B. HIV and drug allergy. Curr Opin Allergy Clin Immunol. 2001;1:311-6.
2. Temesgen Z, Beri G. HIV and drug allergy. Immunol Allergy Clin North Am. 2004;24:521-31.
3. Rotunda A, Hirsch R, Scheinfeld N, Weinberg J. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83:1-9.
4. a ed. Barcelona: Permanyer; 2005.
5. Séguin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol. 2003;3:235-42.
6. Vilar FJ, Naisbitt DJ, Park BK, Pirmohamed M. Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system. J HIV Ther. 2003;8:42-7.
7. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology. 2002;181-182:55-63.
8. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
9. Baier-Bitterlich G, Fuchs D, Wachter H. Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection. Biochem Pharmacol. 1997;53:755-63.
10. Naisbitt DJ, Vilar J, Stalford A, Wilkins EGL, Pirmohamed M, Park BK. Plasma cysteine and decreased reduction of nitroso sulphametoxazole with HIV infection. AIDS Res Hum Retroviruses. 2000;16 Suppl 18:1929-38.
11. Kano Y, Inaoka M, Shiohara T. Association between anticonvulsivant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol. 2004;140:183-8.
12. Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis. 1998;27:1321-2.
13. Claudio GA, Martín AF, De Dios Perrino S, Velasco AA. DRESS syndrome associated with nevirapine therapy. Arch Intern Med. 2001;161:2501-2.
14. Knudtson E, Para M, Boswell H, Van-Havard P. Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet Gynecol. 2003;101:1094-7.
15. Lanzafame M, Rovere P, De Checchi G, Trevenzoli M, Turazzini M, Parrinello A. Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy. Scand J Infect Dis. 2001;33:475-6.
16. Bersoff-Matcha SJ, Miller WC, Aberg JA, Van Der Horst C, Hamrick Jr HJ, Powderly WG, et al. Sex differences in nevirapine rash. Clin Infect Dis. 2001;32:124-9.
17. Ho TTY, Wong KH, Chan KCW, Lee SS. High incidence of nevirapine- associated rash in HIV-infected Chinese. AIDS. 1998;12:2082-3.
18. Patel SM, Johnson S, Belknap SM, Chan J, Sha BE, Bennett C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Defic Syndr. 2004;35:120-5.
19. Estrada V, De Villar N, Serrano-Ríos M. Reacciones adversas cuténeas asociadas al tratamiento con nevirapina y vacunación antineumocócica en pacientes con infección por el virus de la inmunodeficiencia humana. Med Clin (Barc). 2001;116:479.
20. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005;19 Suppl 1:97-9.
21. Wit F, Wood R, Horban A, Beniowski M, Schmidt RE, Gray G, et al. Prednisone does not prevent hypersensitivity reactions in antirretroviral drug regimens containing abacavir with or without nevirapine. AIDS. 2001;15:2423-9.
22. Rey D, Partisani M, Krantz V, Kempf G, Nicolle M, De Mautort E, et al. Prednisolone does not prevent the occurrence of nevirapine-induced rashes. AIDS 1999;13:2307.
23. Barreiro P, Soriano V, González-LaHoz J. Prevention of nevirapine-as-sociated rash. Lancet. 2001;357:392.
24. Knobel H, Miró JM, Domingo P, Rivero A, Márquez M, Force L, et al. Failure of a short-term prednisone regimen to prevent nevirapine-asociated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 Study Group. J Acquir Immune Defic Syndr. 2001;28:14-8.
25. Launay O, Roudier L, Boukli N, Dupont B, Prevoteau du Clary F, Patey O, et al. Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial. Clin Infect Dis. 2004;15;38:e66-72.
26. Demoly P, Messaad D, Fabre J, Reynes J, Bousquet J. Nevirapine-induced cutaneous hypersensitivity reactions and successful tolerance induction. J Allergy Clin Immunol. 1999;104:504-5.
27. Messaad D, Reynes J, Fabre J, Bousquet J, Demoly P. Long-term safety and efficacy of nevirapine tolerance induction. Clin Exp Allergy. 2002;32:733-5.
28. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS. 2001;15:1843-8.
29. Blitz M, Spivack E, Kerpel SM, Freedman PD. Stevens-Johnson syndrome in an HIV-infected patient. AIDS Read. 1999;9:184-5,190.
30. Cattelan AM, Trevenzoli M, Sasset L, Sgarabotto D, Lanzafame M, Meneghetti F. Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature. J Infect. 2001;43:246-9.
31. Vera Mendez F, Martinez O, García J, Garcia J, Vilaplana R. [Toxic epidermal necrolysis in relation with nevirapine]. An Med Interna. 2000;17:448-9.
32. Wetterwald E, Le Cleach L, Michel C, David F, Revuz J. Nevirapine-induced overlap Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 1999;140:980-2.
33. Soriano V, Dona C, Barreiro P, González-Lahoz J. Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash? AIDS. 2000;14:1672-3.
34. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis. 2000;30:227-8.
35. Phillips EJ, Kuriakose B, Knowles S. Efavirenz-induced skin eruption and successful desensitization. Ann Pharmacother. 2002;36:430-2.
36. Foti J, Piatt J. Hypersensitivity to efavirenz treated with corticosteroids in a 6-year-old child. AIDS Patient Care STDS. 2003;17:1-3.
37. Behrens GM, Stoll M, Schmidt RE. Pulmonary hypersensitivity reaction induced by efavirenz. Lancet. 2001;357:1503-4.
38. Clarke S, Harrington B, Barry M, Mulcahy F. The tolerability of efavirenz after nevirapine-related adverse events. Clin Infect Dis. 2000;31:806-7.
39. Podzamezer D, Consiglio E, Ferrer E, Gudiol F. Efavirenz associated with corticosteroids in patients with previous severe hypersensitivity reaction due to nevirapine. AIDS. 2000;14:331-2.
40. Treudler R, Husak R, Raisova M, Orfanos C, Tebbe B. Efavirenz-induced photoallergic dermatitis in HIV. AIDS. 2001;15:1085-6.
41. Newell A, Avila C, Rodgers ME. Photosensitivity reaction to efavirenz. Sex Transm Infect 2000;76:221.
42. López-Lerma I, Alsina M, Blanco JL, Lecha M. Photodermatitis in a patient with HIV infection. J Am Acad Dermatol. 2003;49:159-60.
43. Yoshimoto E, Konishi M, Takahashi K, Murakawa K, Maeda K, Mikasa K, et al. The first case of efavirenz-induced photosensitivity in a Japanese patient with HIV infection. Intern Med. 2004;43:630-1
44. Furue M. Photosensitive drug eruption induced by efavirenz in a patient with HIV infection. Intern Med. 2004;43:533.
45. Domingo P, Barceló M. Efavirenz-induced leukocytoclastic vasculitis. Arch Intern Med. 2002;162:355-6.
46. Mills G, Morgan J, Hales G, Smith D. Acute hypersensitivity with delavirdine. Antivir Ther. 1999;4:51.
47. Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther. 2002;24:1502-14.
48. Hewitt RG: Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34:1137-42.
49. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Therapeutics. 2001;23: 1603-14.
50. Hetherington S. Understanding drug hypersensitivity: What to look for when prescribing abacavir. AIDS reader. 2001;11:620-2.
51. Del Valle Loarte P, Cervero Jiménez M, Joya Seijo MD, Jusdado Ruiz-Capillas JJ, Torres Perea R. Síndrome de sensibilidad retardada a fármacos. Rev Clin Esp. 2003;203:615-8.
52. Abacabir hypersensitivity reaction. AIDS Patient Care STDS. 2002;16:242.
53. Hypersensitivity reactions reported with abacavir. AIDS Patient Care STDS. 1998;12:405-6.
54. De la Rosa R, Harris M, Uyeda L, Goodison K, Keown P, Montaner JSG. Life-threatening reaction after first ever dose of abacavir in an HIV-1 infected patient. AIDS. 2004;18:578-9.
55. El Sahly HM. Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient. AIDS. 2004;18:359-60.
56. Frissen PHJ, Vries J, Weigel H, Brinkman K. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. AIDS. 2001;15:289.
57. Shapiro M, Ward KM, Stern JJ. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. AIDS read. 2001;11:222-6.
58. Clay PG, Rathbun RC, Slater LN. Management protocol for abacavir-related hypersensitivity reaction. Ann Pharmacother. 2000;34:247-9.
59. Severe hypersensitivity reactions following reintroduction of abacavir. AIDS Read. 2000;10:525.
60. Keiser P, Nassar N, Skiest D, Andrews C, Yazdani B, White A, et al. Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction. Int J STD AIDS. 2003;14:478-81.
61. Aquilina C, Mularczyk M, Lucas F, Viraben R. Unusual clinical presentation of hypersensitivity reaction to abacavir. AIDS. 2003;17:2403-4.
62. Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS. 2002;16:2223-5.
63. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, et al. Predisposition to abacavir hypersensitivity conferred by HLA B*5701 and a haplotypic Hsp 70-Hom variant. Proc Natl Acad Sci USA. 2004;23:4180-5.
64. Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, et al. Clinical and immunologenetic correlates of abacabir hypersensitivity. AIDS. 2005;19:979-81.
65. King D, Tomkins S, Waters A, Easterbrook PJ, Chir B, Thurmond LM, et al. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects. J Allergy Clin Immunol. 2005;115:1081-7.
66. Loeliger AE, Steel H, McGuirk S, Powell W, Hetherington SV. The abacavir hypersensitivity reaction and interruptions in therapy. AIDS. 2001;15:1325-6.
67. Easterbrook PJ, Waters A, Murad S, Ives N, Taylor C, King D, et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med. 2003;4:321-4.
68. Symonds W, Cutrell A, Edwards M, Steel H, Spreen B, Powell G, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther. 2002;24:565-73.
69. Chirouze C, Hustache-Mathieu L, Rougeot C, Drobacheff C, Gil H, Faller JP, et al. [Risk factors for abacavir-induced hypersensitivity syndrome in the «real world»]. Pathol Biol (Paris). 2004;52:529-33.
70. Cutrell AG, Hernandez JE, Fleming JW, Edwards MT, Moore MA, Brothers CH, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004;38:2171-2.
71. Peyrieere H, Nicolas J, Siffert M, Demoly P, Hillaire-Buys D, Reynes J. Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother. 2001;35:1291-2.
72. Flexner C. HLA B57 and abacavir hypersensitivity. Hopkins HIV Rep. 2002;14 Suppl 3:5.
73. Hughes AR, Mosteller M, Bansal AT, Davies K, Hanelina SA, Lai EH, et al. Association of genetic variations in HLA B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5:203-11.
74. Veenstra DL. Bringing genomics to the bedside: a cost-effective pharmacogenomic test. Pharmacogenetics. 2004;14:33-4.
75. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004;14:335-42.
76. Watson ME, Pimenta JM, Spreen WR, Hernandez JE. HLA B* 5701 and abacavir hypersensitivity. Pharmacogenetics. 2004;14:783-4.
77. Abacavir hypersensitivity reaction predicted by genetic test. AIDS treat News. 2004;26:6.
78. Wassef M, Keiser P. Hypersensitivity to zidovudine: report of a case of anaphylaxis and review of the literature. Clin Infect Dis. 1995;20:1387-9.
79. Torres RA, Lin RY, Lee M, Barr MR. Zidovudine-induced leukocytoclastic vasculitis. Arch Intern Med. 1992;152:850-1.
80. Slayter KL, Pierce SM, Marrie TJ. Possible zidovudine-associated hypersensitivity. Ann Pharmacother. 1996;30:1197.
81. McKinley GF, Mazza DS, Grieco MH. Urticarial reaction to zidovudine. Lancet. 1990;336-384.
82. Carr A, Penny R, Cooper DA. Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS). J Allergy Clin Immunol. 1993;91:683-5.
83. Murri R, Antinori A, Camilli G, Zannoni G, Patriarca G. Fatal toxic epidermolysis induced by zidovudine. Clin Infect Dis. 1996;23:640-1.
84. Kainer MA; Mijch A. Anaphylactoid reaction, angioedema, and urticaria associated with lamivudine. Lancet. 1996;348:1519.
85. Smith KJ, Buckley R, Skelton H. Lamivudine (3TC)-induced contact dermatitis. Cutis. 2000;65:227-9
86. Herranz P, Fernández-Díaz ML, De Lucas R, González-García J, Casado M. Cutaneous vasculitis associated with didadosine. Lancet. 1994;344:680.
87. Parneix-Spake A, Bastuji-Garin S, Levy Y, Dubreil-Lemaire ML, Roujeau J. Didanosine as probable cause of Steven-Johnson syndrome. Lancet. 1992;340:857-8
88. Bonfanti P, Capetti A, Riva P, Testa L, Quirino T. Hypersensitivity reactions during antiretroviral regimens with protease inhibitors. AIDS. 1997;11:1301-2.
89. Floridia M, Bucciardini R, Fragola V, Galluzzo CM, Giannini G, Pirillo MF, et al. Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (< 50 cells/μL). HIV Med. 2004;5:1-10.
90. Demoly P, Messaad D, Trylesinski A, Faucherre V, Fabre J, Reynes J et al. Nelfinavir-induced urticaria and successful desensitization. J Allergy Clin Immunol. 1998;102:875-6.
91. Calista D, Boschini A. Cutaneous side effects induced by indinavir. Eur J Dermatol. 2000;10:292-6.
92. Rijnders B, Kooman J. Severe allergic reaction after repeated exposure to indinavir. Clin Infect Dis. 1998;26:523-4.
93. Fung HB, Pecini R, Brown S, Gropper CA. Indinavir-associated maculopapular eruption. Pharmacother. 1999;19:1328-30.
94. Woolley I, Tapley N, Korman M. Sequencial cutaneous drug reactions to protease inhibitors in the context of occupational post-exposure prophylaxis. AIDS. 2003;17:1709-15.
95. Rachline A, Lariven S, Descamps V, Grossin M, Bouvet E. Leucocytoclastic vasculitis and indinavir. B J Dermatol. 2000;143:1112-3.
96. Ball RA, Kinchelow T. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol. 2003;49:826-31.
97. Maggi P, Ladisa N, Cinori E, Altobella A, Pastore G, Filotico R. Cutaneous injection site reactions to long term therapy with enfuvirtide. J Antimicrob Chemother. 2004;53:678-81.
98. Shahar E, Moar C, Pollack S. Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction. AIDS. 2005;19:451-2.
99. De Simone JA, Ojha A, Pathak R, Conn J. Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1 infected man. Clin Infect Dis. 2004;39:e110-2.
100. Moreno Rodilla E. Reacciones de hipersensibilidad a medicamentos en el paciente con infección por el VIH. En: Lobera T, Audicana MT, editores. Alergia a medicamentos. Madrid: Sanidad; 2005. p. 205-26.